Access denied. You must log in to view this page.
The purpose of the Simmons Cancer Center Grand Rounds is to fulfill the need to provide oncology physicians, scientists, residents, clinical fellows, and other interested individuals with the latest information and research on advances in cancer etiology, pathogenesis and therapeutics. Eminent cancer research scholars and physicians will be brought to the Simmons Cancer Center to discuss and disseminate this knowledge through lectures, audio/video presentations, case studies, syllabi or other handouts, and question and answer sessions.
Target Audience
The target audience for this program is UT Southwestern faculty, physicians, residents, and fellows in Oncology, e.g., Medical, Pediatric, Surgical, Radiation and Neurological.
Learning Objectives
The overall objectives of this program are to utilize the latest cancer therapeutics in the most effective way possible for the benefit of UT Southwestern Medical Center at Dallas cancer patients.
At the conclusion of this program, participants should be able to integrate the latest peer reviewed cancer research scholarship and knowledge into their clinical and translational research programs and translate the clinical and research experiences and knowledge of their peers and eminent scholars into new and emerging cancer research and patient care.
UT Southwestern Medical Center
5323 Harry Hines Blvd.
NB2EEF AUDITORIUM
Dallas, TX
75390
United States
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Immunomedics;.
has no relevant financial relationships to disclose at this time.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Novartis;.
has no relevant financial relationships to disclose at this time.